Five things for pharma marketers to know:
- The Centers for Medicare and Medicaid Services announced plans to broadly cover a new class of Alzheimer’s drugs pending approval by the Food and Drug Administration.
- Sandoz said it plans to move to a new central Basel headquarters by mid-2024 following its proposed spin-off from Novartis.
- Eikon Therapeutics announced three business development deals, effectively dropping in a pipeline of cancer drugs alongside more than $100 million in fresh funding.
- AstraZeneca and Merck’s Lynparza gained an expanded prostate cancer indication from the FDA.
- The Supreme Court gave a boost to whistleblowers in their bid to revive lawsuits accusing pharmacy operators of knowingly overbilling government health insurance programs for prescription drugs at taxpayers’ expense.
![[column] Toekomst tijdschriften glanst als nooit tevoren](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/happy-couple-in-t-shirts-reading-newspaper-while-h-2024-11-10-00-13-23-utc-1-80x60.jpg)
![[column] MarketingAffairs 17: Marketing als oplossing](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/asian-seo-manager-writing-on-glass-with-illustrati-2024-11-17-23-11-51-utc-1-80x60.jpg)
